JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths - PubMed (original) (raw)
. 2012 Mar 22;119(12):2721-30.
doi: 10.1182/blood-2011-11-395228. Epub 2012 Jan 25.
Affiliations
- PMID: 22279053
- DOI: 10.1182/blood-2011-11-395228
Free article
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Ayalew Tefferi. Blood. 2012.
Free article
Abstract
On November 16, 2011, the Food and Drug Administration approved ruxolitinib (a JAK1 and JAK2 inhibitor) for use in the treatment of high and intermediate risk myelofibrosis. This is welcome news for those patients in whom such therapy is indicated and treatment benefit outweighs attendant risk. The question is who are these patients, what should they expect in terms of both short-term effects and long-term impact, and why would they choose ruxolitinib over other JAK inhibitors that are freely available for use in a research setting. Ruxolitinib and most other JAK inhibitors exert a salutary effect on constitutional symptoms and splenomegaly but have yet to produce histopathologic or cytogenetic remissions, reverse bone marrow fibrosis, or improve survival over best supportive care. Furthermore, the palliative value of JAK inhibitors is diminished by notable side effects, including anemia, thrombocytopenia, gastrointestinal disturbances, metabolic abnormalities, peripheral neuropathy, and hyperacute relapse of symptoms during treatment discontinuation. Therefore, risk-benefit balance favors use of currently available JAK inhibitors in only a select group of patients with myelofibrosis, and their potential value in polycythemia vera, outside of special circumstances (eg, intractable pruritus), is undermined by the absence of evidence for a disease-modifying effect and presence of arguably superior alternatives.
Similar articles
- Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C, Tam CS, Verstovsek S. Arana Yi C, et al. Future Oncol. 2015;11(5):719-33. doi: 10.2217/fon.14.272. Future Oncol. 2015. PMID: 25757677 Free PMC article. Review. - Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Kantarjian HM, et al. Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):638-45. doi: 10.1016/j.clml.2013.09.006. Epub 2013 Oct 2. Clin Lymphoma Myeloma Leuk. 2013. PMID: 24238036 Free PMC article. Review. - Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO. Kremyanskaya M, et al. Oncology (Williston Park). 2013 Jul;27(7):706-14. Oncology (Williston Park). 2013. PMID: 23977767 Review. - Ruxolitinib: a new treatment option for myelofibrosis.
Ganetsky A. Ganetsky A. Pharmacotherapy. 2013 Jan;33(1):84-92. doi: 10.1002/phar.1165. Pharmacotherapy. 2013. PMID: 23307549 Review. - The future of JAK inhibition in myelofibrosis and beyond.
Mascarenhas JO, Cross NC, Mesa RA. Mascarenhas JO, et al. Blood Rev. 2014 Sep;28(5):189-96. doi: 10.1016/j.blre.2014.06.002. Epub 2014 Jun 28. Blood Rev. 2014. PMID: 25043171 Review.
Cited by
- JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib.
Wijaya I, Bashari MH, Reniarti L, Rahmawati A, Roesli RMA. Wijaya I, et al. Dis Markers. 2024 Apr 12;2024:2906566. doi: 10.1155/2024/2906566. eCollection 2024. Dis Markers. 2024. PMID: 38716474 Free PMC article. - Characterizing the microbiome of patients with myeloproliferative neoplasms during a Mediterranean diet intervention.
Avelar-Barragan J, Mendez Luque LF, Nguyen J, Nguyen H, Odegaard AO, Fleischman AG, Whiteson KL. Avelar-Barragan J, et al. mBio. 2023 Dec 19;14(6):e0230823. doi: 10.1128/mbio.02308-23. Epub 2023 Oct 25. mBio. 2023. PMID: 37877698 Free PMC article. - Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A, Pardanani A, Gangat N. Tefferi A, et al. Haematologica. 2023 Nov 1;108(11):2919-2932. doi: 10.3324/haematol.2022.282612. Haematologica. 2023. PMID: 36861402 Free PMC article. - Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations.
Yuan J, Song J, Chen C, Lv X, Bai J, Yang J, Zhou Y. Yuan J, et al. Invest New Drugs. 2022 Dec;40(6):1194-1205. doi: 10.1007/s10637-022-01297-5. Epub 2022 Aug 31. Invest New Drugs. 2022. PMID: 36044173 - A Novel Morphological Parameter Predicting Fibrotic Evolution in Myeloproliferative Neoplasms: New Evidence and Molecular Insights.
Fiorentino V, Tralongo P, Martini M, Betti S, Rossi E, Pierconti F, De Stefano V, Larocca LM. Fiorentino V, et al. Int J Mol Sci. 2022 Jul 17;23(14):7872. doi: 10.3390/ijms23147872. Int J Mol Sci. 2022. PMID: 35887218 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous